ReAlta Life Sciences Receives FDA Clearance for Phase 2 Trial of RLS-0071 in Hospitalized Patients with Steroid-Refractory Acute Graft-Versus-Host Disease...
Read MoreNorfolk, VA, September 5, 2023 – ReAlta Life Sciences (“ReAlta”), Inc., a clinical mid-stage biotech company addressing life-threatening rare diseases...
Read MoreNORFOLK, Va., August 1, 2023 — ReAlta Life Sciences (“ReAlta”), Inc., a clinical mid-stage biotech company dedicated to addressing life-threatening...
Read MoreNorfolk, VA, June 27, 2023 – ReAlta Life Sciences (“ReAlta”), Inc., a company addressing life-threatening rare diseases through harnessing the...
Read MoreNorfolk, VA, June 1, 2023 – ReAlta Life Sciences (“ReAlta”), Inc., a company addressing life-threatening rare diseases through harnessing the...
Read MorePresenting proof-of-mechanism clinical trial data in healthy volunteers of RLS-0071, the Company’s dual action complement inhibitor and innate anti-inflammatory product...
Read MoreNorfolk, VA, June 1st, 2022 – ReAlta Life Sciences, Inc. (“ReAlta”) a clinical stage, rare disease company addressing life-threatening diseases...
Read MoreInhaled LPS Challenge Trial to Support Development of RLS-0071 in Severe Asthma RLS-0071 is ReAlta’s lead dual action complement inhibitor...
Read MoreRLS-0071 is a dual action complement inhibitor and innate anti-inflammatory peptide in development as a treatment for hypoxic-ischemic encephalopathy and...
Read More